Sugi Predict

Sugi Predict / Compounds / SCHEMBL18970801

SCHEMBL18970801

SCHEMBL18970801

CC(C)(C)OC(=O)NCCS(N)(=O)=O

nearest known ligand 0.57

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.51
▸ CA1 P00915 12/20 0.51
▸ CA2 P00918 12/20 0.51
▸ CA12 O43570 9/20 0.51
▸ CA9 Q16790 7/20 0.51
▸ MAOA P21397 1/20 0.49
▸ MAOB P27338 1/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ GAA P10253 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ EPHX1 P07099 1/20 0.43
▸ MALT1 Q9UDY8 1/20 0.40
▸ CA14 Q9ULX7 2/20 0.40
▸ CA7 P43166 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5908856 0.89 TDP1 (0.57) TDP1CA1CA2CA12CA9
SCHEMBL24297067 0.86 TDP1 (0.63) TDP1CA1CA2CA12CA9
SCHEMBL5213233 0.83 TDP1 (0.53) TDP1CA1CA2CA12CA9
SCHEMBL7352046 0.83 TDP1 (0.58) TDP1CA1CA2CA12CA9
SCHEMBL1455954 0.82 TDP1 (0.57) TDP1CA1CA2CA12CA9
SCHEMBL5209649 0.81 TDP1 (0.51) TDP1CA1CA2CA12CA9
Hydrochloric Acid SCHEMBL29948784 0.81 TDP1 (0.56) TDP1CA1CA2CA12CA9
SCHEMBL6402383 0.81 TDP1 (0.51) TDP1CA1CA2CA12CA9
SCHEMBL22015366 0.81 TDP1 (0.47) TDP1CA1CA2CA12CA9
SCHEMBL2422789 0.80 CA2 (0.50) TDP1CA1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361253-A1 STING AGONIST COMPOUNDS SUTRO BIOPHARMA INC (US) 2025-11-27 — — US disclosed
EP-4536672-A1 STING AGONIST COMPOUNDS Sutro Biopharma, Inc. (US) 2025-04-16 — — EP disclosed
CN-119654330-A STING agonist compounds 苏特罗生物制药公司 2025-03-18 — — CN disclosed
US-12157731-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2024-12-03 — — US disclosed
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2024-09-05 — — US disclosed
EP-4347579-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN Captor Therapeutics S.A. (PL) 2024-04-10 — — EP disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
WO-2023239675-A1 STING AGONIST COMPOUNDS SUTRO BIOPHARMA, INC. (US) 2023-12-14 — — WO disclosed
WO-2023239675-A1 STING AGONIST COMPOUNDS SUTRO BIOPHARMA, INC. (US) 2023-12-14 — — WO disclosed
WO-2021178488-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2021-09-10 — — WO disclosed
US-20200206362-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS Moderna TX, Inc. (US) 2020-07-02 — — US disclosed
US-10556018-B2 Compositions and methods for delivery of agents ARES CAPITAL CORPORATION, AS AGENT 2020-02-11 — — US disclosed
US-20190117798-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS MODERNATX, INC. (US) 2019-04-25 — — US disclosed
US-10207010-B2 Compositions and methods for delivery of agents MODERNATX, INC. (US) 2019-02-19 — — US disclosed
US-20180147298-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS MODERNATX, INC. (US) 2018-05-31 — — US disclosed
US-20180147298-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS MODERNATX, INC. (US) 2018-05-31 — — US disclosed
US-20180028664-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS MODERNATX, INC. (US) 2018-02-01 — — US disclosed
US-20180028664-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS MODERNATX, INC. (US) 2018-02-01 — — US disclosed
WO-2017099823-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS MODERNATX, INC. (US) 2017-06-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190117798-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS HDLBP, APOB, TSG101 TDP1 753/4885CA1 3608/4885CA2 4137/4885
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 TDP1 1025/4885CA1 4317/4885CA2 3669/4885
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN MCL1, MDM2, XIAP TDP1 3302/4885CA1 3478/4885CA2 4467/4885
US-10556018-B2 Compositions and methods for delivery of agents HDLBP, APOB, TSG101 TDP1 753/4885CA1 3608/4885CA2 4137/4885
US-12157731-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 TDP1 1025/4885CA1 4317/4885CA2 3669/4885
US-20200206362-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS HDLBP, APOB, TSG101 TDP1 753/4885CA1 3608/4885CA2 4137/4885
US-10207010-B2 Compositions and methods for delivery of agents HDLBP, APOB, TSG101 TDP1 753/4885CA1 3608/4885CA2 4137/4885
US-20250361253-A1 STING AGONIST COMPOUNDS STING1, CGAS, MAVS TDP1 223/4885CA1 4883/4885CA2 4743/4885
US-20180147298-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS HDLBP, APOB, TSG101 TDP1 753/4885CA1 3608/4885CA2 4137/4885
US-20180028664-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS HDLBP, APOB, TSG101 TDP1 753/4885CA1 3608/4885CA2 4137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.